CRL · Charles River Laboratories International, Inc.

Current Thesis

Charles River Laboratories’ demand-recovery continuation thesis broke at the 2026-09-18 weekly close; the 2026-09-24 Investor Day now tests the operating case after the published price condition failed. The adjusted close of $278.06 breached the $280 weekly threshold stated in the 2026-09-05 dossier. That outcome is already observable and cannot be deferred until management presents.

The earlier explanation that analyst activity had stopped also needs correction. Evercore ISI raised its target to $320 from $300 on 2026-09-11, according to Benzinga’s dated ratings table; Argus raised its target to $330 from $250 on 2026-09-17 in its published research summary. Fresh analyst support arrived, but the September 18 close remained below the published threshold.

As an interpretation of that breach, the narrative is dead for the previously published August continuation leg — the 2026-09-18 weekly close settled its price test. This does not establish that customer demand has reversed: the operating evidence remains the bookings and revenue figures reported on 2026-08-05.

Bullish and bearish views on Charles River Laboratories International, Inc.

The model's bull view on Charles River Laboratories International, Inc. (CRL), in brief: Bookings support the recovery argument. On the 2026-08-05 earnings call, Discovery and Safety Assessment (DSA) reported second-quarter net bookings of $701 million, net book-to-bill of 1.19 times and backlog of $1.97 billion. Book-to-bill exceeded one for the third consecutive… The bear view: The published price condition failed. The week-ending 2026-09-18 adjusted close was $278.06, below the $280 threshold published on 2026-09-05. The continuation thesis therefore failed its stated test before Investor Day. Demand improvement has uneven margins. DSA’s… Both cases follow in full.

Bull Case

• Bookings support the recovery argument. On the 2026-08-05 earnings call, Discovery and Safety Assessment (DSA) reported second-quarter net bookings of $701 million, net book-to-bill of 1.19 times and backlog of $1.97 billion. Book-to-bill exceeded one for the third consecutive quarter, meaning orders exceeded recognized revenue.
• Organic revenue returned to growth. The 2026-08-05 results reported second-quarter organic revenue growth of 0.1%, including 0.2% in DSA. These figures support an operating inflection, although the first positive quarter after nine quarters without organic growth is too small a sample to establish a durable expansion.
• Analyst expectations moved higher again. Evercore’s 2026-09-11 target increase to $320 and Argus’s 2026-09-17 increase to $330 extend the analyst repricing beyond August. These are attributed analyst forecasts, not company financial commitments. Benzinga; Argus.

Bear Case

• The published price condition failed. The week-ending 2026-09-18 adjusted close was $278.06, below the $280 threshold published on 2026-09-05. The continuation thesis therefore failed its stated test before Investor Day.
• Demand improvement has uneven margins. DSA’s second-quarter operating margin was 25.6%, down 180 basis points year over year, in the 2026-08-05 results. Research Models and Services (RMS) organic revenue declined 1.4% in the same quarter. Positive consolidated organic growth did not establish recovery across every segment.
• Adjusted earnings obscure a material gap. The 2026-08-05 guidance update raised full-year adjusted earnings per share to $11.15–$11.45 while cutting earnings per share under generally accepted accounting principles to $3.05–$3.35. The two measures describe materially different earnings outcomes. Company results.

Setup & Price Structure

The 2026-09-18 adjusted close of $278.06 was 6.9% below the supplied 52-week high of $298.58, despite a three-month price increase of 53.2%. The 14-period relative strength index (RSI) measured 39.4, compared with 51.5 on 2026-09-04. These observations establish weaker momentum and a broken published threshold; they do not identify who transacted.

Attention remained visible: company records list healthcare conference appearances on 2026-09-14 and 2026-09-15, while the September analyst increases added fresh coverage. Those events correct the prior dossier’s unconfirmed early-September conference estimate. Company conference announcement, 2026-09-11.

The 2026-09-15 retrospective investment-return headline adds evidence of retail-facing coverage, but this small headline sample cannot establish crowded ownership. Current fund flows, short interest and distance above a moving average are missing; no positioning conclusion follows from the price increase alone.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Investor Day. The company’s 2026-08-05 release schedules the webcast for 9:00 a.m. Eastern Time. The event tests whether management supplies quantified long-term growth and margin targets supporting the recovery argument. Absence of those targets would leave that framework unsubstantiated; their publication would not reverse the already-recorded price invalidation. Company announcement.

What Would Change Our Mind

The loss of the published August threshold is decisive: a weekly close below $280 ends the continuation thesis, and the $278.06 close on 2026-09-18 met that condition. Moving the threshold lower would change the original test after the outcome.

A subsequent weekly close above $280, accompanied by quantified growth and margin targets at the 2026-09-24 Investor Day, would provide grounds for a new assessment. Any such assessment would need its own observable conditions; neither event would erase the September 18 breach. The available evidence does not include comparable long-term analyst growth and margin estimates, so target publication alone cannot establish an expectations beat.

Correlation Notes

This remains a single-name recovery assessment. On 2026-08-05, management linked weaker North American research-model volumes to constrained academic and government spending, citing flat National Institutes of Health budgets and slower grant processing. That identifies an operating exposure; it does not measure CRL’s return correlation with biotechnology equities.

The same quarter’s positive DSA organic growth and negative RMS organic growth show why a broad biotechnology-demand explanation is incomplete. No dated peer-return analysis establishes sector confirmation for the 2026-09-18 price structure.